Mga Batayang Estadistika
| CIK | 1566044 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to VYNE Therapeutics Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission file number 001-38356 VYNE THERAPEUTICS IN |
|
| August 14, 2025 |
VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update Exhibit 99.1 VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update · Implemented cost reductions extend cash runway into first half of 2027 BRIDGEWATER, N.J., August 14, 2025 - VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| July 30, 2025 |
Exhibit 99.2 Repibresib (VYN201) Phase 2b Topline Results Repibresib in Subjects with Non-segmental Vitiligo July 2025 Forward Looking Statements and Important Notes This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the clinical development of VYNE’s product candidate |
|
| July 30, 2025 |
Exhibit 99.1 VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75 Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from Baseline in F-VASI and T-VASI at 3% Concentration Company Will Terminate Extensi |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission file number 001-38356 VYNE THERAPEUTICS I |
|
| May 8, 2025 |
VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update Exhibit 99.1 VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update •Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025 •Expected cash runway into 2H 2026 BRIDGEWATER, N.J., May 8, 2025 - VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated t |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 8, 2025 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission File |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File Number 001-3 |
|
| March 6, 2025 |
List of Subsidiaries of VYNE Therapeutics Inc. Exhibit 21.1 List of Subsidiaries of VYNE Therapeutics Inc. Name (Jurisdiction) VYNE Pharmaceuticals Inc. (Delaware) |
|
| March 6, 2025 |
Tay Therapeutics Ltd Dundee University Incubator 3 James Lindsay Place Dundee DD1 5JJ VYNE Therapeutics Inc. |
|
| March 6, 2025 |
Exhibit 99.1 VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update •Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025 •VYN202 Phase 1b psoriasis trial initiated with results anticipated by year-end 2025 •Expected cash runway into 2H 2026 BRIDGEWATER, N.J., March 6, 2025 - VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” |
|
| March 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 6, 2025 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 6, 2025 |
VYNE THERAPEUTICS INC. INSIDER TRADING POLICY (Effective as of March 19, 2020, as amended from time to time) Explanatory Note While the provisions of Section D of this policy only apply to the Company’s officers, directors and employees (collectively, “Restricted Persons”), Sections A, B, C and E of this policy apply to all employees, consultants who may become aware of material non-public informa |
|
| January 13, 2025 |
Exhibit 99.1 Corporate Presentation January 2025 Forward Looking Statements and Important Notes This presentation by VYNE Therapeutics Inc. (“VYNE”) includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, but not limited to, statements regarding VYNE’s development plans and timelines for repibresib (VYN201) and VYN202, VYNE’s InhiBE |
|
| January 13, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| December 23, 2024 |
VYN202 P1a SAD/MAD Data December 2024 Exhibit 99.2 VYN202 P1a SAD/MAD Data December 2024 Forward Looking Statements and Important Notes This presentation by VYNE Therapeutics Inc . (“VYNE”) includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, but not limited to, statements regarding VYNE’s development plans and timelines for VYN 201 and VYN 202 , VYNE’s InhiBET pla |
|
| December 23, 2024 |
Exhibit 99.1 VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor · Promising results support VYN202’s potential as a novel, once-daily oral treatment for a broad range of immune-mediated disorders · Consistent with Phase 1a SAD results, VYN202 demonstrated a favorable safety and tolerability profile with no drug-related adverse events his |
|
| December 23, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2024 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commissio |
|
| December 19, 2024 |
As filed with the Securities and Exchange Commission on December 19, 2024 As filed with the Securities and Exchange Commission on December 19, 2024 Registration No. |
|
| December 19, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 VYNE THERAPEUTICS INC. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value per share 457(c) and 457(h) 1,520,000(1)(2) |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 VYNE Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38356 45-3757789 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 12, 2024 |
amendment to VYNE Therapeutics Inc. 2023 Equity Incentive Plan Exhibit 10.1 VYNE THERAPEUTICS INC. FIRST AMENDMENT TO 2023 EQUITY INCENTIVE PLAN This First Amendment (this “Amendment”) to the VYNE Therapeutics Inc. 2023 Equity Incentive Plan (as may be amended from time to time, the “Plan”) is dated as of November 6, 2024 (the “Effective Date”). Any capitalized terms that are used but not defined in this Amendment shall have the meanings given to such terms i |
|
| November 14, 2024 |
SC 13G/A 1 ea0221047-13ga2soleusvyne.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* VYNE THERAPEUTICS INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92941V 308 (CUSIP Number) September 30, 2024 (Date of Event Which Re |
|
| November 12, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| November 7, 2024 |
VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update •VYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for mid-2025 •Reported positive first-in-human Phase 1a SAD data for VYN202, with MAD data expected in Q4 2024 BRIDGEWATER, N.J., November 7, 2024 - VYNE Ther |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission file number 001-38356 VYNE THERAPEUTI |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 7, 2024 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| September 12, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 12, 2024 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commissio |
|
| September 12, 2024 |
Exhibit 99.1 VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor · VYN202 was generally well tolerated with no drug-related adverse events · Pharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood · Pharmacodynamic activity observed on target engagement and inflammatory biomarkers · Dosing has begun in the MAD portion of th |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 14, 2024 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission F |
|
| August 14, 2024 |
VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update •Initiated Phase 2b trial of VYN201 in nonsegmental vitiligo, with top-line results expected in mid-2025 •Phase 1a SAD/MAD trial of VYN202 progressing, with data from the SAD and MAD portions expected in Q3 and Q4 2024, respectively •Balance sheet expected to fund key clinical milestones for V |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission file number 001-38356 VYNE THERAPEUTICS IN |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 9, 2024 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission File |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission file number 001-38356 VYNE THERAPEUTICS I |
|
| May 9, 2024 |
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 VYNE Reports First Quarter 2024 Financial Results and Provides Business Update •Design of Phase 2b trial for VYN201 in nonsegmental vitiligo finalized and on track to begin this quarter •Phase 2b trial expected to enroll approximately 160 subjects with either active or stable nonsegmental vitiligo and will evaluate VYN201 gel in 1%, 2% and 3% concentrations compared to vehicle for 24 |
|
| March 12, 2024 |
VYNE Therapeutics Inc. 685 Route 202/206 N., Suite 301 Bridgewater, New Jersey 08807 VYNE Therapeutics Inc. 685 Route 202/206 N., Suite 301 Bridgewater, New Jersey 08807 March 12, 2024 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Doris Stacey Gama Re: VYNE Therapeutics Inc. Registration Statement on Form S-3 File No. 333-277609 Acceleration Request Requested Date: March 14, 2024 Requested |
|
| March 1, 2024 |
VYNE Therapeutics Inc. 2024 Inducement Plan. Exhibit 4.4 VYNE THERAPEUTICS INC. 2024 INDUCEMENT PLAN 1. General. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq IM 5635-1. A person who previously s |
|
| March 1, 2024 |
As filed with the Securities and Exchange Commission on March 1, 2024 As filed with the Securities and Exchange Commission on March 1, 2024 Registration No. |
|
| March 1, 2024 |
As filed with the Securities and Exchange Commission on March 1, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 1, 2024 Registration No. |
|
| March 1, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 VYNE THERAPEUTICS INC. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value per share 457(c) and 457(h) 500,000(1)(2) $2 |
|
| March 1, 2024 |
Exhibit 10.3 VYNE THERAPEUTICS INC. $50,000,000 SALES AGREEMENT March 1, 2024 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: VYNE Therapeutics Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of this Agree |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File Number 001-3 |
|
| March 1, 2024 |
Exhibit 4.6 VYNE Therapeutics Inc. Restricted Share Unit Grant Notice (2024 Inducement Plan) VYNE Therapeutics Inc. (formerly Menlo Therapeutics Inc.) (the “Company”), pursuant to its 2024 Inducement Plan (the “Plan”), hereby awards to Participant a Restricted Share Unit Award for the number of Shares (“Restricted Share Units”) set forth below (the “Award”). The Award is subject to all of the term |
|
| March 1, 2024 |
VYNE Therapeutics Inc. Incentive Compensation Recoupment Policy, dated November 8, 2023. VYNE Therapeutics Inc. Incentive Compensation Recoupment Policy NOVEMBER 8, 2023 1.Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of VYNE Therapeutics Inc., a Delaware corporation (the “Company”), and the Board have determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Rec |
|
| March 1, 2024 |
Non-Employee Director Compensation Policy. Exhibit 10.17 VYNE THERAPEUTICS INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) who is not also serving as an employee of VYNE Therapeutics Inc. (the “Company”) (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) for his or her Board service effective |
|
| March 1, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) VYNE Therapeutics Inc. |
|
| March 1, 2024 |
Form of Share Option Grant Notice and Option Agreement under the 2024 Inducement Plan. Exhibit 4.5 VYNE Therapeutics Inc. Share Option Grant Notice (2024 Inducement Plan) VYNE Therapeutics Inc. (formerly Menlo Therapeutics Inc.) (the “Company”), pursuant to its 2024 Inducement Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of Shares set forth below. This option is subject to all of the terms and conditions as set forth in this Share Option Grant No |
|
| March 1, 2024 |
List of Subsidiaries of VYNE Therapeutics Inc. Exhibit 21.1 List of Subsidiaries of VYNE Therapeutics Inc. The following is a list of subsidiaries of VYNE Therapeutics Inc. as of December 31, 2023: Name Jurisdiction VYNE Pharmaceuticals Ltd.* Israel VYNE Pharmaceuticals Inc. Delaware *The Company is in the process of liquidating and dissolving this subsidiary. |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 29, 2024 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| February 29, 2024 |
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update Exhibit 99.1 VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update · 2023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a successful financing with a syndicate of leading institutional investors · Anticipate commencing a Phase 2b trial for VYN201 and a Phase 1a trial for VYN202 in Q2 2024 |
|
| February 14, 2024 |
US92941V3087 / VYNE THERAPEUTICS INC / CITADEL ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* VYNE Therapeutics Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (the “Shares”) (Title of Class of Securities) 92941V308 ( |
|
| February 2, 2024 |
SC 13G/A 1 ea192420-13ga1soleusvyne.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* VYNE Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92941V 308 (CUSIP Number) December 31, 2023 (Date of Event Which Requ |
|
| January 3, 2024 |
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors Exhibit 99.1 VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors BRIDGEWATER, N.J., January 3, 2024 - VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the appointment of Christine |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 29, 2023 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| December 13, 2023 |
Form of Director Option Grant Notice and Option Agreement under the 2023 Equity Incentive Plan Exhibit 10.2 For US Director VYNE Therapeutics Inc. Share Option Grant Notice (2023 Equity Incentive Plan) VYNE Therapeutics Inc. (formerly Menlo Therapeutics Inc.) (the "Company"), pursuant to its 2023 Equity Incentive Plan (the "Plan"), hereby grants to Optionholder an option to purchase the number of Shares set forth below. This option is subject to all of the terms and conditions as set forth |
|
| December 13, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 VYNE THERAPEUTICS INC. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule(3) Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(3) Equity Common Stock, $0.0001 par value per share 457(c) and 457(h) 2,339,6 |
|
| December 13, 2023 |
Form of Employee Option Grant Notice and Option Agreement under the 2023 Equity Incentive Plan. Exhibit 10.3 VYNE Therapeutics Inc. Share Option Grant Notice (2023 Equity Incentive Plan) VYNE Therapeutics Inc. (formerly Menlo Therapeutics Inc.) (the “Company”), pursuant to its 2023 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of Shares set forth below. This option is subject to all of the terms and conditions as set forth in this Share Op |
|
| December 13, 2023 |
Exhibit 10.4 VYNE Therapeutics Inc. Restricted Share Unit Grant Notice (2023 Equity Incentive Plan) VYNE Therapeutics Inc. (formerly Menlo Therapeutics Inc.) (the “Company”), pursuant to its 2023 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Share Unit Award for the number of Shares (“Restricted Share Units”) set forth below (the “Award”). The Award is subject to al |
|
| December 13, 2023 |
As filed with the Securities and Exchange Commission on December 13, 2023 As filed with the Securities and Exchange Commission on December 13, 2023 Registration No. |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 11, 2023 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| December 13, 2023 |
VYNE Therapeutics Inc. 2023 Equity Incentive Plan. Exhibit 10.1 VYNE THERAPEUTICS INC. 2023 EQUITY INCENTIVE PLAN 1. General. (a) Successor to 2019 Plan and 2018 Plan. The Plan is intended as the successor to the Menlo Therapeutics Inc. 2019 Equity Incentive Plan, as amended from time to time (the “2019 Plan”) and the Menlo Therapeutics Inc. 2018 Omnibus Incentive Plan (the “2018 Plan”). (i) Any Shares that would o |
|
| November 22, 2023 |
39,266,980 Shares Common Stock Offered by the Selling Stockholders TABLE OF CONTENTS Filed pursuant to Rule 424(b)(3) Registration No. 333-275507 PROSPECTUS 39,266,980 Shares Common Stock Offered by the Selling Stockholders This prospectus relates to the proposed resale from time to time of up to 39,266,980 shares, or the Shares, of our common stock, par value $0.0001 per share, or the common stock, by the selling stockholders named herein, together with any ad |
|
| November 20, 2023 |
VYNE Therapeutics Inc. 685 Route 202/206 N., Suite 301 Bridgewater, New Jersey 08807 VYNE Therapeutics Inc. 685 Route 202/206 N., Suite 301 Bridgewater, New Jersey 08807 November 20, 2023 Via Edgar United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Doris Stacey Gama RE: VYNE Therapeutics Inc. Registration Statement on Form S-3 File No. 333-275507 Acceleration Request Requested Date: November 22, 2023 Req |
|
| November 13, 2023 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of November 13, 2023, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the “Filers”). Each of the Filers may be required to file wit |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 13, 2023 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| November 13, 2023 |
EX-99.4 2 d570190dex994.htm EX-99.4 Exhibit 99.4 Joint Filing Agreement The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is respons |
|
| November 13, 2023 |
EX-99.1 2 tm2330557d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of VYNE Therapeutics Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, |
|
| November 13, 2023 |
VYNE / VYNE Therapeutics Inc / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* VYNE Therapeutics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92941V100 (CUSIP Number) November 1, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| November 13, 2023 |
VYNE / VYNE Therapeutics Inc / AI Biotechnology LLC - SC 13D Activist Investment SC 13D 1 d570190dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* VYNE Therapeutics Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 92941V100 (CUSIP Number) Alejandro Moreno Langhorne S. Perrow c/o Access Industries, Inc. 40 West 57th Street, 28th Fl |
|
| November 13, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) VYNE Therapeutics Inc. |
|
| November 13, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| November 13, 2023 |
US92941V3087 / VYNE THERAPEUTICS INC / CITADEL ADVISORS LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* VYNE Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (the “Shares”) (Title of Class of Securities) 92941V308 (C |
|
| November 13, 2023 |
Exhibit 99.1 VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of 2025 Phase 2b preparatory activities progressing for VYN201 in nonsegmental vitiligo following positive Phase 1b results On track for VYN202 IND submiss |
|
| November 13, 2023 |
EX-99.5 3 d570190dex995.htm EX-99.5 Exhibit 99.5 LIMITED POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Lincoln Benet and Alejandro Moreno, and each of them individually, the undersigned’s true and lawful attorney-in-fact to: • execute for and on behalf of the undersigned, in the undersigned’s capacity as a beneficial owner of VYNE Therapeutics I |
|
| November 13, 2023 |
US92941V3087 / VYNE THERAPEUTICS INC / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)* VYNE Therapeutics Inc. (Name of Issuer – as specified in its charter) Common Stock, par value $0.0001 (Title of Class of Securities) 92941V308 (CUSIP Number) November 1, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission file number 001-38356 VYNE THERAPEUTI |
|
| November 13, 2023 |
As filed with the Securities and Exchange Commission on November 13, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 13, 2023 Registration No. |
|
| November 2, 2023 |
VYNE / VYNE Therapeutics Inc / Soleus Capital Master Fund, L.P. - SCHEDULE 13G Passive Investment SC 13G 1 ea187561-13gsoleusvyne.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* VYNE Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92941V 308 (CUSIP Number) November 1, 2023 (Date of Event Which Requires Filing of this State |
|
| October 30, 2023 |
Exhibit 99.4 Corporate Presentation October 2023 Forward Looking Statements and Important Notes This presentation by VYNE Therapeutics Inc ..(" includes forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, but not limited to, statements regarding VYNE's plans, regulatory filings and development timelines for VYN 201 and VYN 202 VYNE's Inh |
|
| October 30, 2023 |
Form of Pre-Funded Warrant to Purchase Common Stock. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 30, 2023 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of October 27, 2023, between VYNE Therapeutics Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purcha |
|
| October 30, 2023 |
Exhibit 99.2 VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo · Clinical proof-of-concept achieved with statistically significant dose dependent reduction in F-VASI score from baseline for the VYN201 1.0% and 2.0% cohorts compared to the 0.5% cohort · VYN201 was generally well-tolerated with no clinically relevant t |
|
| October 30, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 27, 2023, between VYNE Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). Whereas, subject to the terms and conditio |
|
| October 30, 2023 |
VYNE Therapeutics Announces Private Placement of $88 Million Exhibit 99.1 VYNE Therapeutics Announces Private Placement of $88 Million · Transaction provides $88 million to fund VYNE’s clinical development programs for VYN201 and VYN202 through the end of 2025 BRIDGEWATER, N.J., October 30, 2023 - VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 27, 2023 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| October 30, 2023 |
Exhibit 99.3 VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202 · Treatment with VYN202 resulted in significant inhibition of key inflammatory biomarkers and substantial resolution of the signs and symptoms of psoriasis and rheumatoid arthritis · Following completion of recent financing, VYNE expects to initiate a Phase 1a SAD/MAD clinica |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 14, 2023 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission F |
|
| August 14, 2023 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS HAVE BEEN MADE LICENSE AGREEMENT (ORAL) This LICENSE AGREEMENT (the “Agreement”) is made and entered into effective as of April 28, 2023 (the “Effective Date”) by and be |
|
| August 14, 2023 |
Exhibit 99.1 VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Anticipate announcing preliminary Phase 1b safety and efficacy data for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in Q3 2023 IND-enabling studies for VYN202, a potential best-in-class oral small molecule BD2-selective BET inhibitor, are ongoing in anticipation of indication select |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission file number 001-38356 VYNE THERAPEUTICS IN |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 11, 2023 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission File |
|
| May 11, 2023 |
Exhibit 99.1 VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update Anticipate topline 16-week data for all three cohorts from the Phase 1b trial for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in the third quarter of 2023 IND-enabling studies for VYN202, a potential best-in-class oral small molecule BD2-selective BET inhibitor, are ongoing in antici |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission file number 001-38356 VYNE THERAPEUTICS I |
|
| May 11, 2023 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. |
|
| May 1, 2023 |
Exhibit 99.1 VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions Preclinical studies suggest VYN202 has the potential to be the most potent and selective BET inhibitor in development VYN202 has demonstrated a potent anti-inflammatory and anti-fibrotic eff |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 28, 2023 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File Number 001-3 |
|
| March 14, 2023 |
Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 VYNE Therapeutics Inc., a Delaware corporation (“we,” “us” or “our”), has one class of securities registered under Section 12 of the Securities Exchange Act of 1934: our common stock, $.0001 par value per share. The general terms and provisions of our common stock are summarized below. This sum |
|
| March 14, 2023 |
List of Subsidiaries of VYNE Therapeutics Inc. EX-21.1 3 exhibit211listofsubsidiari.htm EX-21.1 Exhibit 21.1 List of Subsidiaries of VYNE Therapeutics Inc. The following is a list of subsidiaries of VYNE Therapeutics Inc. as of December 31, 2022: Name Jurisdiction VYNE Pharmaceuticals Ltd.* Israel VYNE Pharmaceuticals Inc. Delaware *The Company is in the process of liquidating and dissolving this subsidiary. |
|
| March 9, 2023 |
Exhibit 99.1 VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update First vitiligo patients being treated with pan-BD BET inhibitor, VYN201, for up to 16 weeks in Phase 1b clinical trial Anticipate topline Phase 1b data in mid-2023 BRIDGEWATER, N.J., March 9, 2023 - VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical c |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 9, 2023 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission Fil |
|
| February 28, 2023 |
VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule Exhibit 99.1 VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule BRIDGEWATER, N.J., February 28, 2023 - VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that it received a notif |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 27, 2023 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| February 10, 2023 |
Certificate of Amendment to the Amended and Restated Certificate of Incorporation. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VYNE THERAPEUTICS INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware VYNE THERAPEUTICS INC., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as f |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 8, 2023 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| January 17, 2023 |
Exhibit 3.1 CERTIFICATE OF ELIMINATION OF SERIES A CONVERTIBLE PREFERRED STOCK OF VYNE THERAPEUTICS INC. Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware VYNE THERAPEUTICS INC., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRS |
|
| January 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 17, 2023 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| January 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 12, 2023 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| November 25, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| November 14, 2022 |
VYNE THERAPEUTICS INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, David Domzalski, does hereby certify that: 1. David Domzalski is the Chief Executive Officer of VYNE THERAPEUTICS INC., a Delaware corporation (the ?Corporation?). 2. The Corporation is authorized to is |
|
| November 14, 2022 |
REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of November 11, 2022, between VYNE THERAPEUTICS INC. |
|
| November 14, 2022 |
AMENDED AND RESTATED BYLAWS OF VYNE THERAPEUTICS INC. (a Delaware corporation) Effective November 10, 2022 TABLE OF CONTENTS ARTICLE I - CORPORATE OFFICES 1.1 REGISTERED OFFICE 1.2 OTHER OFFICES ARTICLE II - MEETINGS OF STOCKHOLDERS 2.1 PLACE OF MEETINGS 2.2 ANNUAL MEETING 2.3 SPECIAL MEETING 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2.5 ADVANCE NOTICE PROCEDURES FOR NOMI |
|
| November 14, 2022 |
SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of November 11, 2022, between VYNE Therapeutics Inc. |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission file number 001-38356 VYNE THERAPEUTI |
|
| November 14, 2022 |
PRE 14A 1 tm2230379-1pre14a.htm PRE 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ( |
|
| November 10, 2022 |
Exhibit 99.1 VYNE Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update IND clearance received for pan-BD BET inhibitor, VYN201; Anticipate first patient to be enrolled in Phase 1a/b trial for Vitiligo this month Continued progression of discovery and development of oral, BD2 selective VYN202 program Expanded analysis of FMX114 Phase 2a trial results suggests FMX11 |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 10, 2022 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| November 10, 2022 |
INVESTOR PRESENTATION November 2022 Exhibit 99.2 INVESTOR PRESENTATION November 2022 Forward Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 199 including, but not limited to, statements regarding clinical development and timelines for VYNE?s BET inhibitor platform, VYNE?s development strategy for FMX 114 and its potential treatment effe |
|
| August 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 29, 2022 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission F |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission file number 001-38356 VYNE THERAPEUTICS IN |
|
| August 12, 2022 |
VYNE Therapeutics Reports Second Quarter 2022 Financial Results Exhibit 99.1 VYNE Therapeutics Reports Second Quarter 2022 Financial Results BRIDGEWATER, N.J., August 12, 2022 - VYNE Therapeutics Inc. (Nasdaq: VYNE) (?VYNE? or the ?Company?), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three and six months ended June 3 |
|
| August 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 12, 2022 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission F |
|
| August 12, 2022 |
June 15, 2022 Tay Therapeutics Attn: Andrew Woodland Dear Andrew: Reference is made to the Evaluation and Option Agreement (the ?OLA?) dated as of April 30, 2021 by and between Tay Therapeutics (formerly known as In4Derm Limited) (?In4Derm?) and VYNE Therapeutics Inc. |
|
| August 10, 2022 |
Exhibit 99.1 VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis BRIDGEWATER, N.J., August 10, 2022 - VYNE Therapeutics Inc. (Nasdaq: VYNE) (?VYNE? or the ?Company?), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announc |
|
| August 10, 2022 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 10, 2022 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission F |
|
| July 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| July 27, 2022 |
Exhibit 99.1 The InhiBET TM Platform Bromodomain & End Terminal (BET) Inhibitors in Autoimmune Disease Iain Stuart, Ph.D Chief Scientific Officer B&T Cell - Mediated Autoimmune Disease Drug Development Conference, July 27, 2022 1 Forward Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , including, |
|
| July 27, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 27, 2022 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 19, 2022 |
DEFA14A 1 tm2221301d1defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by R |
|
| July 7, 2022 |
DEFA14A 1 tm2217544d3defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by R |
|
| June 17, 2022 |
Exhibit 99.1 VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis Top-line Efficacy Results Expected in Approximately 6 to 8 Weeks BRIDGEWATER, N.J., June 17, 2022 - VYNE Therapeutics Inc. (Nasdaq: VYNE) (?VYNE? or the ?Company?), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for th |
|
| June 17, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULFE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant??? ???????? ??? ?????????Filed by a party other than the Registrant??? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permit |
|
| June 17, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 15, 2022 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 7, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULFE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant??? ???????? ??? ?????????Filed by a party other than the Registrant??? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permit |
|
| May 17, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 17, 2022 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission File |
|
| May 17, 2022 |
KOL Event: Update on the BET InhiBET Platform and VYN201 May 17, 2022 Exhibit 99.1 KOL Event: Update on the BET InhiBET Platform and VYN201 May 17, 2022 Forward Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , including, but not limited to statements regarding the development of VYNE?s product candidates, the timing of its clinical trials and regulatory filings and |
|
| May 12, 2022 |
Exhibit 99.1 VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update Announced positive Phase 1b data for FMX114 in mild-to-moderate atopic dermatitis Lead BET inhibitor VYN201 demonstrated positive results across multiple preclinical models of inflammation VYNE to host KOL webinar on InhiBETTM BET inhibitor platform on May 17th BRIDGEWATER, N.J., May 12, 2022 - |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 12, 2022 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission File |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission file number 001-38356 VYNE THERAPEUTICS I |
|
| May 12, 2022 |
Up to $14,385,585 of Shares Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-255841 AMENDMENT NO. 1 DATED MAY 12, 2022 to Prospectus Supplement dated August 12, 2021 (To Prospectus dated May 14, 2021) Up to $14,385,585 of Shares Common Stock This Amendment No. 1 to Prospectus Supplement (this ?Amendment?) amends our prospectus supplement dated August 12, 2021 (the ?Prospectus Supplement?). This Amendment should be read |
|
| April 7, 2022 |
Letter from PricewaterhouseCoopers LLP, dated April 6, 2022. EX-16.1 2 tm228420d7ex16-1.htm EXHIBIT 16.1 Exhibit 16.1 April 6, 2022 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by VYNE Therapeutics Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K of VYNE Therapeutics Inc. dated April 6, 2022. We |
|
| April 7, 2022 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 6, 2022 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 7, 2022 |
Exhibit 99.1 VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis ? At week 2, FMX114 demonstrated a statistically significant reduction in both absolute and percent change in ADSI score compared to vehicle ? Phase 2a safety and efficacy results expected in the second quarter BRIDGEWATER, N.J., April 7 |
|
| March 30, 2022 |
Exhibit 99.1 VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis ? VYN201 demonstrated statistically significant improvement in treatment response for both endpoints at 1mg/kg and 10mg/kg doses ? VYN201 also demonstrated numerically superior results at 1mg/kg and 10mg/kg doses compared to leading injectable |
|
| March 30, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 30, 2022 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 17, 2022 |
Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934 Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, VYNE Therapeutics Inc. (the ?Company?) had common stock, $0.0001 par value per share, registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), and listed on The Nasdaq Global Market under the trading symbol ?VYNE.? DESCRIPTION |
|
| March 17, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) VYNE THERAPEUTICS INC. |
|
| March 17, 2022 |
As filed with the Securities and Exchange Commission on March 17, 2022 As filed with the Securities and Exchange Commission on March 17, 2022 Registration No. |
|
| March 17, 2022 |
Offer Letter, dated as of March 15, 2022, by and between VYNE Pharmaceuticals Inc. and Tyler Zeronda Vyne Therapeutics Inc. 520 U.S. Highway 22, Suite 204, Bridgewater, New Jersey 08807 March 15, 2022 Dear Tyler, This letter (the ?Offer Letter?) contains the terms and conditions of your employment with VYNE Pharmaceuticals Inc. (the ?Company?), a subsidiary of VYNE Therapeutics Inc. (?VYNE?), effective as of March 15, 2022 (the ?Effective Date?). The Company, together with its ultimate parent and |
|
| March 17, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 17, 2022 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 17, 2022 |
Offer Letter, dated as of March 7, 2022, by and between VYNE Pharmaceuticals Inc. and Iain Stuart. Vyne Therapeutics Inc. 520 U.S. Highway 22, Suite 204, Bridgewater, New Jersey 08807 March 7, 2022 Dr. Iain Stuart Dear Iain, This letter (the ?Offer Letter?) contains the terms and conditions of your employment with VYNE Pharmaceuticals Inc. (the ?Company?), a subsidiary of VYNE Therapeutics Inc. (?VYNE?), effective as of March 7, 2022 (the ?Effective Date?). The Company, together with its ultima |
|
| March 17, 2022 |
Exhibit 99.1 VYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate Update FMX114 demonstrated preliminary clinical safety and pharmacokinetics in Phase 1b study VYN201 shows promising preclinical data in 3 well-established and validated inflammation models BRIDGEWATER, N.J., March 17, 2022 - VYNE Therapeutics Inc. (Nasdaq: VYNE) (?VYNE? or the ?Company?), a biopharmaceut |
|
| March 17, 2022 |
List of Subsidiaries of VYNE Therapeutics Inc. Exhibit 21.1 List of Subsidiaries of VYNE Therapeutics Inc. The following is a list of subsidiaries of VYNE Therapeutics Inc. as of December 31, 2021: Name Jurisdiction VYNE Pharmaceuticals Ltd.* Israel VYNE Pharmaceuticals Inc. Delaware *The Company is in the process of liquidating and dissolving this subsidiary. |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File Number 001-3 |
|
| March 17, 2022 |
Amended and Restated Certificate of Incorporation. Exhibit 3.1 MENLO THERAPEUTICS INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Menlo Therapeutics Inc., a corporation organized and existing under and by virtue of the Delaware General Corporation Law, hereby certifies as follows: The name of the corporation is Menlo Therapeutics Inc. The original Certificate of Incorporation of the corporation was filed with the Secretary of State of the S |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 VYNE Therapeutics Inc. |
|
| March 15, 2022 |
Up to $30,000,000 of Shares of Common Stock and 1,667,593 Shares of Common Stock TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5) ?Registration No. 333-255841? PROSPECTUS SUPPLEMENT (To Prospectus dated May 14, 2021) Up to $30,000,000 of Shares of Common Stock and 1,667,593 Shares of Common Stock ? This prospectus supplement relates to the issuance and sale of up to $30,000,000 of shares of our common stock that we may sell to Lincoln Park Capital Fund, LLC (?Lincoln Park?) |
|
| March 15, 2022 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of March 15, 2022, is entered into by and between VYNE THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the ?Investor?). Capitalized terms used herein and not otherwise d |
|
| March 15, 2022 |
Purchase Agreement, dated as of March 15, 2022, by and between the Company and Lincoln Park. Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the ?Agreement?), dated as of March 15, 2022, is made by and between VYNE THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the ?Investor?). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, |
|
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 8, 2022 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 7, 2022 |
Exhibit 99.1 VYNE Reports Positive Preclinical Data for Lead BET Inhibitor, VYN201, in Human Skin Model of Vitiligo ? VYN201 0.1% and 1% resulted in statistically significant improvement in reducing both melanocyte loss and key inflammatory biomarkers involved in the pathogenesis of vitiligo, an immune-modulated skin disorder. ? VYN201 0.1% and 1% demonstrated upregulaton of the WNT signalling pat |
|
| March 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 7, 2022 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 4, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 28, 2022 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| February 15, 2022 |
Exhibit 1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. |
|
| February 15, 2022 |
VYNE / Vyne Therapeutics Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* VYNE Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92941V 209 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| January 19, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 19, 2022 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| January 19, 2022 |
Exhibit 99.1 VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis Systemic bioavailability of JAK inhibitor (tofacitinib) and S1P receptor modulator (fingolimod) in topical formulation substantially lower compared to oral equivalents Mean Cmax of tofacitinib 50-fold and 1500-fold lower at Day 1 and 14 of study compared |
|
| January 14, 2022 |
Unaudited Pro Forma Condensed Consolidated Financial Information Exhibit 99.1 Unaudited Pro Forma Condensed Consolidated Financial Information Overview On January 12, 2022 (the ?Effective Date?), VYNE Therapeutics Inc. (the ?Company? or ?VYNE?) entered into an Asset Purchase Agreement (the ?Agreement?) with Journey Medical Corporation (?Journey? or ?Buyer?) pursuant to which the Company sold its Molecule Stabilizing Technology (MSTTM) franchise, including AMZEE |
|
| January 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 12, 2022 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorpo |
|
| January 13, 2022 |
Exhibit 99.1 VYNE Therapeutics Divests Topical Minocycline Assets Transaction includes cash payments of $25 million and potential milestones of up to $450 million Sale aligns with VYNE?s strategic plan; proceeds will be used to fund development of Company?s immuno-inflammatory pipeline BRIDGEWATER, N.J., January 13, 2022 - VYNE Therapeutics Inc. (Nasdaq: VYNE) (?VYNE? or the ?Company?) today annou |
|
| January 13, 2022 |
Exhibit 2.1 EXECUTION VERSION CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH ?[***].? ASSET PURCHASE AGREEMENT BETWEEN VYNE THERAPEUTICS INC. AND JOURNEY MEDICAL CORPORATION DATED A |
|
| January 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 12, 2022 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| January 5, 2022 |
INVESTOR PRESENTATION January 2022 EX-99.1 2 tm221532d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 INVESTOR PRESENTATION January 2022 Forward Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , including, but not limited to statements regarding the development of VYNE’s product candidates and other statements regarding the future expectatio |
|
| January 5, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 5, 2022 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission F |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission file number 001-38356 VYNE THERAPEUTI |
|
| November 10, 2021 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH ?[***]? TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. LICENSE AGREEMENT (TOPICAL) This License Agreement (the ?Agreement?) is made and entered into effective as of August 9, 2021 (the ?Effective Date?) by an |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 10, 2021 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| November 10, 2021 |
Exhibit 99.1 VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update Lead BET Inhibitor Candidate, VYN201, Demonstrates Potent Anti-Inflammatory Effect in Preclinical Studies VYN201 Expected to Enter Clinic in 2022 Phase 2a Results for FMX114 in Mild-to-Moderate Atopic Dermatitis Expected Early Q1 2022 Process for Sale of Topical Minocycline Franchise Continues |
|
| November 10, 2021 |
INVESTOR PRESENTATION November 2021 Exhibit 99.2 INVESTOR PRESENTATION November 2021 Forward Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , including, but not limited to statements regarding the development of VYNE?s product candidates and other statements regarding the future expectations, plans and prospects of VYNE . All state |
|
| November 10, 2021 |
Exhibit 10.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH ?[***]? TO INDICATE WHERE OMISSIONS HAVE BEEN MADE. EVALUATION AND OPTION AGREEMENT This Evaluation and Option Agreement (?Option Agreement?) is entered into as of April 30, 2021 (the ?Effective Date?) by |
|
| November 4, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 4, 2021 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| November 4, 2021 |
Exhibit 99.1 Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass and Overall Skin Repair Outcomes in Preclinical Study Results support continued progression of VYN201 development program for autoimmune skin diseases BRIDGEWATER, N.J., November 4, 2021 - VYNE Therapeutics Inc. (Nasdaq: VYNE) (?VYNE? or the ?Company?) today announced preclinical data from a validate |
|
| October 26, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 26, 2021 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| October 26, 2021 |
Exhibit 99.1 Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflammatory Cytokines in Preclinical Studies - VYN201 exhibits anti-inflammatory effect in preclinical data similar to a super-potent glucocorticosteroid - VYN201 appeared well-tolerated in mice, as seen through animal body weight and skin condition - VYN201 also demonstrates stronger inhibition of key Th |
|
| October 19, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 19, 2021 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| October 19, 2021 |
Exhibit 99.1 VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis Important milestone achieved as part of the Company?s new corporate strategy to develop treatments for immuno-inflammatory diseases Topline results anticipated in early Q1 2022 BRIDGEWATER, N.J., October 19, 2021 - VYNE Therapeutics Inc. (Nasdaq: VYNE) (?VYNE? or |
|
| September 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 2, 2021 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| August 25, 2021 |
EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. |
|
| August 25, 2021 |
VYNE / Vyne Therapeutics Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* VYNE Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92941V 209 (CUSIP Number) August 17, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission file number 001-38356 VYNE THERAPEUTICS IN |
|
| August 12, 2021 |
INVESTOR PRESENTATION August 2021 Exhibit 99.3 Forward Looking Statements 2 This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to statements regarding the development and commercialization of VYNE?s products and product candidates and other statements regarding the future expectations, plans a |
|
| August 12, 2021 |
Exhibit 99.2 VYNE Therapeutics Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory Conditions with In4Derm Limited VYNE will have exclusive access to a library of new chemical entities VYNE will prioritize initial development efforts on rare skin diseases and major immunology and inflammatory conditions with high unmet needs VYNE expects to enter VYN201 and VYN202 into the clinic |
|
| August 12, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| August 12, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| August 12, 2021 |
Up to $50,000,000 of Shares Common Stock TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5) ?Registration No. 333-255841? PROSPECTUS SUPPLEMENT (To Prospectus dated May 14, 2021) Up to $50,000,000 of Shares Common Stock ? We have entered into a Controlled Equity OfferingSM sales agreement with Cantor Fitzgerald & Co., or Cantor Fitzgerald, relating to shares of our common stock offered by this prospectus supplement and the accompanying |
|
| August 12, 2021 |
Exhibit 1.1 VYNE Therapeutics Inc. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement August 12, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: VYNE Therapeutics Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cantor Fitzgerald & Co. (the ?Agent?), as follows: 1.?????? |
|
| August 12, 2021 |
Exhibit 99.1 VYNE Therapeutics Reports Second Quarter 2021 Financial Results and Announces New Strategic Direction to Develop Treatments for Immunological and Inflammatory Diseases Company announced license agreement with In4Derm Limited for BETi platform earlier this morning Company has initiated a process to explore a sale or license of its topical minocycline franchise Phase 2a results for FMX1 |
|
| August 12, 2021 |
Exhibit 99.1 Explanatory Note The COVID-19 pandemic and government measures taken in response to the pandemic have had a negative impact on the Company's operations. Access to healthcare providers has been limited, which has negatively impacted sales and the Company's ability to execute its commercial strategy with respect to AMZEEQ and ZILXI. In addition, the commercial launches of both AMZEEQ an |
|
| August 12, 2021 |
Offer Letter, dated as of June 7, 2021, by and between Tyler Zeronda and VYNE Pharmaceuticals Inc. Exhibit 10.1 June 7, 2021 Tyler Zeronda Dear Tyler, This letter (the ?Offer Letter?) contains the terms and conditions of your employment with VYNE Pharmaceuticals Inc. (the ?Company?), a subsidiary of VYNE Therapeutics Inc. (?VYNE?), effective as of June 18, 2021 (the ?Effective Date?). The Company, together with its ultimate parent and their respective affiliates and subsidiaries, are hereinafte |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 12, 2021 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission F |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 9, 2021 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2021 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 19, 2021 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VYNE THERAPEUTICS INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware VYNE THERAPEUTICS INC., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?Corporation?), does hereby certify as f |
|
| July 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 30, 2021 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| June 7, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ????????? ??? ?????????Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted |
|
| June 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 4, 2021 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission File |
|
| June 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| May 26, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ????????? ??? ?????????Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted |
|
| May 11, 2021 |
VYNE Therapeutics Inc. 520 U.S. Highway 22, Suite 204 Bridgewater, New Jersey 08807 VYNE Therapeutics Inc. 520 U.S. Highway 22, Suite 204 Bridgewater, New Jersey 08807 May 11, 2021 VIA EDGAR AND EMAIL Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Re: VYNE Therapeutics Inc. Request for Acceleration Registration Statement on Form S-3 Filed May 6, 2021 File No. 333-255841 (the ?Registration Statement?) Ladies and Gentlemen: |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission file number 001-38356 VYNE THERAPEUTICS I |
|
| May 6, 2021 |
Exhibit 99.1 VYNE Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update Conference call and live webcast today at 8:30 am Eastern Time BRIDGEWATER, N.J., May 6, 2021 - VYNE Therapeutics Inc. (Nasdaq: VYNE) (?VYNE? or the ?Company?) today announced financial results for the first quarter ended March 31, 2021 and provided a corporate update. ?Our sales organization c |
|
| May 6, 2021 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 6, 2021 Registration No. |
|
| May 6, 2021 |
Offer Letter, dated as of April 7, 2021, by and between VYNE Pharmaceuticals Inc. and Mutya Harsch. Exhibit 10.2 April 7, 2021 Dear Mutya, This letter (the ?Offer Letter?) contains the terms and conditions of your employment with VYNE Pharmaceuticals Inc. (the ?Company?), a subsidiary of VYNE Therapeutics Inc. (?VYNE?), effective as of April 7, 2021 (the ?Effective Date?). The Company, together with its ultimate parent and their respective affiliates and subsidiaries, are hereinafter referred to |
|
| May 6, 2021 |
Offer Letter, dated as of April 7, 2021, by and between Andrew Saik and VYNE Pharmaceuticals Inc. Exhibit 10.1 April 7, 2021, Dear Andrew: This letter (the ?Offer Letter?) contains the terms and conditions of your employment with VYNE Pharmaceuticals Inc. (the ?Company?), a subsidiary of VYNE Therapeutics Inc. (?VYNE?), effective as of April 7, 2021 (the ?Effective Date?). The Company, together with its ultimate parent and their respective affiliates and subsidiaries, are hereinafter referred |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2021 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission File |
|
| April 20, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commissi |
|
| March 30, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 30, 2021 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 30, 2021 |
vyneinvestorpresentation INVESTOR PRESENTATION March 2021 Exhibit 99.1 Forward Looking Statements 2 This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to statements regarding the development and commercialization of VYNE’s products and product candidates and other statements regarding the futu |
|
| March 4, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File Number 001-3 |
|
| March 4, 2021 |
Exhibit 99.1 VYNE Therapeutics Reports Year-End 2020 Financial Results and Provides Business Update Conference call and live webcast to discuss financial results and new FMX114 program in atopic dermatitis today, Thursday, March 4, 2021, at 8:30 am Eastern Time BRIDGEWATER, N.J., March 4, 2021 - VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for t |
|
| March 4, 2021 |
List of Subsidiaries of VYNE Therapeutics Inc. Exhibit 21.1 List of Subsidiaries of VYNE Therapeutics Inc. The following is a list of subsidiaries of VYNE Therapeutics Inc. as of December 31, 2020: Name Jurisdiction VYNE Pharmaceuticals Ltd. Israel VYNE Pharmaceuticals Inc. Delaware |
|
| March 4, 2021 |
As filed with the Securities and Exchange Commission on March 4, 2021 Registration No. |
|
| March 4, 2021 |
investorpresentation2020 INVESTOR PRESENTATION March 2021 Exhibit 99.1 Forward Looking Statements 2 This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to statements regarding the development and commercialization of VYNE’s products and product candidates and other statements regarding the futu |
|
| March 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 4, 2021 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 4, 2021 |
Exhibit 10.11(c) VYNE THERAPEUTICS INC. 2018 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE VYNE Therapeutics Inc., a Delaware corporation, (the ?Company?), pursuant to its 2018 Omnibus Incentive Plan, as amended from time to time (the ?Plan?), hereby grants to the holder listed below (the ?Participant?), an award of restricted stock units (?Restricted Stock Units? or ?RSUs?). Eac |
|
| March 4, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 4, 2021 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 4, 2021 |
Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934 Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2020, VYNE Therapeutics Inc. (the ?Company?) had common stock, $0.0001 par value per share, registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), and listed on The Nasdaq Global Market under the trading symbol ?VYNE.? DESCRIPTION |
|
| March 4, 2021 |
Amended and Restated Certificate of Incorporation. Exhibit 3.1 MENLO THERAPEUTICS INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Menlo Therapeutics Inc., a corporation organized and existing under and by virtue of the Delaware General Corporation Law, hereby certifies as follows: The name of the corporation is Menlo Therapeutics Inc. The original Certificate of Incorporation of the corporation was filed with the Secretary of State of the S |
|
| March 1, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 1, 2021 |
Exhibit 99.1 VYNE Therapeutics Announces Development Program for FMX114 Combination Topical Gel for Mild-to-Moderate Atopic Dermatitis Announces promising preclinical data on FMX114 Phase 2a clinical study in AD expected to begin in 3Q 2021 with top-line results by year end Further details on FMX114, including clinical development plans, will be discussed on VYNE’s year end 2020 earnings call at 8 |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 16, 2021 |
EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. |
|
| February 16, 2021 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Vyne Therapeutics Inc. (formerly known as Menlo Therapeutics Inc.) (Title of Class of |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* VYNE Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92941V 100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2021 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commissio |
|
| February 12, 2021 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VYNE THERAPEUTICS INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware VYNE THERAPEUTICS INC., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?Corporation?), does hereby certify as f |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2021 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commissio |
|
| February 11, 2021 |
VYNE Therapeutics Announces Reverse Stock Split Exhibit 99.1 VYNE Therapeutics Announces Reverse Stock Split BRIDGEWATER, N.J., February 11, 2021 - VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its Board of Directors has approved a reverse stock split of the Company’s common stock at a ratio of 1-for-4. The reverse stock split was previously approved by stockholders at the Annual Meeting of Stockholders he |
|
| February 11, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2021 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commissio |
|
| January 28, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2021 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| January 28, 2021 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 26, 2021, between VYNE Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condition |
|
| January 27, 2021 |
21,097,046 Shares VYNE Therapeutics Inc. Common Stock TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-229482 PROSPECTUS SUPPLEMENT(To Prospectus dated February 12, 2019) 21,097,046 Shares VYNE Therapeutics Inc. Common Stock We are offering 21,097,046 shares of our common stock to several institutional investors pursuant to this prospectus supplement and the accompanying prospectus and a securities purchase agreemen |
|
| January 26, 2021 |
Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2021 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| January 7, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2021 VYNE Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-38356 45-3757789 (State or other jurisdiction of incorporation) (Commission |
|
| January 7, 2021 |
Investor Presentation January 2021 Exhibit 99.1 Investor Presentation January 2021 Forward Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , including, but not limited to statements regarding the development and commercialization of VYNE’s products and product candidates and other statements regarding the future expectations, plans |
|
| November 5, 2020 |
Exhibit 99.1 VYNE Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update Conference Call Today at 8:30am Eastern Time BRIDGEWATER, N.J., November 5th, 2020 - VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the third quarter ended September 30, 2020 and provided a corporate update. “The launch of ZILXI™ on October |
